# Comparisons with Death-free days, Wilcoxon rank sums test.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Group variable** | **n1 (+)** | **n2 (-)** | **Death-free days (+), Median[IQR]** | **Death-free days (-), Median[IQR]** | **U statistic** | **P value** |
| ARDS | 26 | 26 | 16 [ 9·2- 34] | 1·9e+02 [ 15- 3·6e+02] | -2·1 | 0·037 |
| Gender (male) | 24 | 28 | 77 [ 15- 3·6e+02] | 16 [ 8·8- 2·4e+02] | 2·0 | 0·047 |
| Immunosuppressed | 20 | 32 | 16 [ 11- 77] | 53 [ 13- 3·6e+02] | -1·4 | 0·16 |
| Malignancy | 13 | 39 | 15 [ 14- 24] | 69 [ 9·5- 3·6e+02] | -1·1 | 0·27 |
| Piperacillin-tazobactam | 31 | 21 | 17 [ 12- 2·4e+02] | 72 [ 11- 3·6e+02] | -1·0 | 0·31 |
| Diabetes | 18 | 34 | 20 [ 10- 1·3e+02] | 31 [ 11- 3·6e+02] | -0·98 | 0·33 |
| Vancomycin | 28 | 24 | 16 [ 11- 2·8e+02] | 74 [ 13- 3·6e+02] | -0·95 | 0·34 |
| Azithromycin | 9 | 43 | 2·4e+02 [ 14- 3·6e+02] | 24 [ 11- 3·1e+02] | 0·82 | 0·41 |
| Ceftriaxone | 14 | 38 | 90 [ 14- 3·6e+02] | 20 [ 11- 3·3e+02] | 0·81 | 0·42 |
| Septic shock | 28 | 24 | 20 [ 10- 3·6e+02] | 74 [ 12- 3·6e+02] | -0·73 | 0·47 |
| Sepsis-3 | 34 | 18 | 24 [ 14- 3·6e+02] | 43 [ 7·5- 3·4e+02] | 0·69 | 0·49 |
| Ciprofloxacin | 12 | 40 | 20 [ 12- 3·6e+02] | 30 [ 11- 3·6e+02] | -0·098 | 0·92 |